Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines ...

LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.

Eli Lilly and Company and SiteOne Therapeutics, Inc. — a private biotechnology company developing treatments for pain and other neuronal hyper-excitability disorders — today announced a definitive ...

The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne ...

Eli Lilly and Company and SiteOne Therapeutics, Inc., a private biotechnology company developing small molecule inhibitors of ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Eli Lilly and Company has agreed to acquire SiteOne Therapeutics Inc., a private biotech company developing small molecule ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...